A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

PHASE3RecruitingINTERVENTIONAL

Enrollment

438

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

Jaktinib Hydrochloride Tablet

Orally administered, twice a day

Trial Locations (1)

RECRUITING

139 People's Middle Road, Changsha

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY